Who is a good candidate for this treatment

The first question most patients ask is a straightforward one: does this apply to my situation? For ChondroFiller injection in the hip, candidacy comes down to the nature and extent of the cartilage damage rather than age or activity level alone.

The treatment is designed for focal, isolated defects — areas of ICRS Grade III or IV cartilage loss measuring approximately 2–6 cm², where the surrounding articular surface remains reasonably intact. The two most common clinical scenarios that produce this pattern are femoroacetabular impingement (FAI), where abnormal bone contact progressively damages the acetabular lining, and post-traumatic injury, where a discrete cartilage area is lost following a hip dislocation or impact event.

The critical contraindication is widespread joint degeneration. When damage has spread diffusely across the hip, or when Tönnis grade 2–3 osteoarthritis is present at baseline, outcomes are significantly worse — a finding confirmed in a published cohort (Mazek et al. 2021, n=26) where patients with pre-existing advanced OA did not achieve meaningful benefit. An isolated defect in an otherwise preserved joint is a very different clinical picture from early global arthritis.

Before any injection appointment is scheduled, an MRI of the hip is essential. It maps the defect size and grade, assesses the integrity of the subchondral bone beneath the damaged area, and confirms whether the surrounding cartilage is healthy enough for the scaffold to have a stable environment in which to work.

How ChondroFiller works once it is inside the joint

ChondroFiller is not a cell therapy and it does not introduce new cartilage directly. Classified as a CE-marked Class III medical device, it is an acellular Type I collagen hydrogel — meaning it carries no living cells of its own. Its role is structural: to provide a three-dimensional scaffold that the patient's own progenitor cells, drawn from the surrounding synovium and subchondral bone, can migrate into, organise within, and use as a framework for repair. The process is called acellular matrix-induced chondrogenesis.

The behaviour of the material inside the joint determines why placement precision is not optional. Injected as a liquid, ChondroFiller encounters body temperature in the joint space and begins polymerising within approximately 3–5 minutes, setting into a firm, cohesive gel. Once that gelation window closes, the scaffold is fixed wherever it sits. There is no mechanism for redistributing or retrieving it after the fact — which is precisely why confirming needle-tip position inside the defect, before the material is released, is a clinical necessity rather than a technical preference.

That the scaffold genuinely recruits cells is supported by a 2025 ex vivo human osteochondral study, which recorded a 2.4-fold increase in DNA content within ChondroFiller by day 14, confirming active cell migration into the matrix in the early post-implantation period. The scaffold supports the body's own repair processes within the defect boundary; it does not regrow cartilage independently.

Why the hip joint is structurally harder to inject accurately

Three anatomical realities combine to make the hip genuinely different from shallower joints — and each one has a direct bearing on why the procedure is built around image guidance from the outset.

Depth is the first factor. Reaching the anterior joint space requires a needle to travel through four to eight centimetres of overlying soft tissue — roughly three to four times the distance required for a typical knee injection. At that depth, the tactile feedback a clinician might use to sense needle position disappears entirely.

Vascular geography is the second. The femoral artery runs approximately 1.9 cm medial to the anterior capsule; the femoral vein approximately 1.7 cm medial; the femoral nerve approximately 2.3 cm lateral. Crossing directly over the capsule is the lateral circumflex femoral artery (LCFA) — but at a position that differs between patients and cannot be predicted from surface landmarks alone. Colour Doppler ultrasound maps these structures in real time, at that visit, for that patient, before the needle moves.

The third factor follows directly from what the previous section described: once ChondroFiller begins to set, the scaffold is fixed. A mis-deposited gel that polymerises outside the defect cannot be corrected. Depth, vascular variability, and irreversible gelation together make the case for image guidance a structural one, not a procedural preference.

What ultrasound guidance actually changes in practice

The accuracy gap between guidance methods is well documented. A 2016 systematic review by Hoeber and colleagues, covering 120 studies and more than 1,700 hip injections, found that landmark-guided techniques achieved accurate intra-articular placement in 72% of cases (95% CI 56–85%), against 100% (95% CI 98–100%) for image-guided approaches — a difference significant at p<0.0001. Subsequent ultrasound series have consistently reported accuracy in the 97–100% range.

For most injectables, a 28–30% miss rate is a problem of reduced efficacy. For a scaffold that gels in situ within minutes, it is a problem of permanent mis-deposition. Material that sets outside the cartilage defect cannot migrate to the correct position, cannot support cell ingrowth within the target zone, and cannot be retrieved. That distinction matters when evaluating the practical stakes of guidance choice.

Beyond needle placement, real-time ultrasound serves a second role during delivery: monitoring scaffold volume and distribution as the material is introduced. A 2025 arthroscopic study of ChondroFiller in distal radius defects found that flush application produced significantly better cartilage quality outcomes, while overfilling led to fibrous rather than hyaline-type tissue (median Outerbridge score 1.5 versus 3, P=0.006). Only 0.2–0.3 mL per defect site was required — a precision target that real-time imaging helps the clinician meet.

One 2022 landmark-guided protocol did achieve 94.3% accuracy, but the methodology required in-session radiographic confirmation followed by post-injection ultrasound verification. The additional steps involved may be manageable in a research context; they substantially complicate a streamlined outpatient appointment intended to avoid imaging overhead.

Outcomes and recovery: what the evidence shows for the hip

Published results from the hip are limited to a single prospective cohort but cover a follow-up window long enough to be meaningful. Mazek et al. (2021) treated 26 adults arthroscopically for acetabular cartilage lesions greater than 2 cm² associated with femoroacetabular impingement; at three to five years, 17 of 21 evaluable patients achieved good or excellent outcomes, with modified Harris Hip Scores improving by approximately 30 points. That figure is not a universal success rate — five patients were lost to follow-up, and the cohort is small — but it represents the strongest available hip-specific signal for this scaffold.

The selection boundary the data expose is important. Patients with Tönnis grade 2–3 osteoarthritis at baseline showed poor outcomes, which aligns with the eligibility criteria described earlier: when disease is diffuse rather than focal, a scaffold placed in one region cannot address the broader cartilage environment. The 17/21 result is best understood as an outcome among appropriately selected patients, not as a headline rate applicable to every hip presentation.

Recovery carries a specific clinical requirement that should not be underestimated. A 2024 biomechanical in vitro study found that ChondroFiller does not fully protect opposing cartilage under early loading — initial scaffold instability means mechanical stress can transfer before the matrix has adequately stabilised. Post-injection weight-bearing restriction is therefore a necessary part of the protocol, not a precautionary afterthought.

Knee cohort data — including approximately 30-point IKDC improvements at 12 months — provide a corroborating directional signal, but cannot substitute for hip-specific evidence. It should also be noted plainly that no published randomised controlled trial has yet compared ultrasound-guided ChondroFiller injection in the hip against surgical delivery in a matched population; the evidence base, while encouraging, remains observational.

Assessment and next steps at London Cartilage Clinic

For patients who believe they may fit the profile described above, the starting point is a structured assessment rather than an immediate injection appointment. A clinician will review existing MRI to confirm defect size, grade, and subchondral bone integrity, and combine that imaging review with a clinical examination to establish whether the focal defect criteria are genuinely met — and whether the surrounding joint is in a condition likely to support a good outcome. Only once that eligibility decision is made is an injection appointment planned.

At London Cartilage Clinic's Harley Street rooms, that assessment and — where appropriate — the ultrasound-guided injection itself are delivered as outpatient treatments without the need for theatre admission. Professor Paul Y. F. Lee leads hip cartilage assessment at the clinic, integrating imaging review with procedural planning for suitable candidates.

Patients wishing to explore whether ChondroFiller injection may be appropriate for their hip can request a consultation at londoncartilage.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
3. [3] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
4. [4] JP6.3 Utility of ultrasound-guided lateral hip injection using the short-axis image-parallel technique. (2025). https://doi.org/10.1093/jhps/hnaf069.128 https://doi.org/10.1093/jhps/hnaf069.128
5. [5] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759